Enhancement of the immune response by intradermal vaccination in cattle with enterotoxigenic Escherichia coli (ETEC) vaccine without adjuvant

Samina, Itzchak; Jacob, Brenner; R, Avraham; Ben-Ami, Peleg

doi:10.1016/0264-410x(92)90155-d

“…CD4 and CD8 are the markers for helper T cells and cytotoxic T cells respectively. CD19 is the surface marker for antibody producing plasma cells [ 35 ]. It was observed that the markers tested at the site of injection were up- regulated at 24 h post injection in the PBS injection using device as compared to PBS injection using hypodermic syringe ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Insights into the mechanism of a novel shockwave-assisted needle-free drug delivery device driven by in situ-generated oxyhydrogen mixture which provides efficient protection against mycobacterial infections

Subburaj

¹

,

Datey

²

,

Gopalan

³

et al. 2017

View full text Add to dashboard Cite

BackgroundNeedle-free, painless and localized drug delivery has been a coveted technology in the area of biomedical research. We present an innovative way of trans-dermal vaccine delivery using a miniature detonation-driven shock tube device. This device utilizes~2.5 bar of in situ generated oxyhydrogen mixture to produce a strong shockwave that accelerates liquid jets to velocities of about 94 m/s.MethodOxyhydrogen driven shock tube was optimized for efficiently delivering vaccines in the intradermal region in vivo. Efficiency of vaccination was evaluated by pathogen challenge and host immune response. Expression levels of molecular markers were checked by qRT-PCR.ResultsHigh efficiency vaccination was achieved using the device. Post pathogen challenge with Mycobacterium tuberculosis, 100% survival was observed in vaccinated animals. Immune response to vaccination was significantly higher in the animals vaccinated using the device as compared to conventional route of vaccination.ConclusionA novel device was developed and optimized for intra dermal vaccine delivery in murine model. Conventional as well in-house developed vaccine strains were used to test the system. It was found that the vaccine delivery and immune response was at par with the conventional routes of vaccination. Thus, the device reported can be used for delivering live attenuated vaccines in the future.Electronic supplementary materialThe online version of this article (10.1186/s13036-017-0088-x) contains supplementary material, which is available to authorized users.

show abstract

“…Further studies are needed, in particular on the use of a booster vaccination 60 days after primary vaccination, or on the use of a higher dose than the 0.2 IU/mL used in this study. The latter is likely to have lower costs and be more feasible, and increasing the intradermal dose is easier in cattle than humans as cattle skin is relatively thick and it is therefore easier to administer larger quantities of vaccine at one site [41].…”

Section: Discussionmentioning

confidence: 99%

Comparison of antibody titres between intradermal and intramuscular rabies vaccination using inactivated vaccine in cattle in Bhutan

Wangmo

¹

,

Laven

²

,

Cliquet

³

et al. 2019

View full text Add to dashboard Cite

In developing countries, the cost of vaccination limits the use of prophylactic rabies vaccination, especially in cattle. Intradermal vaccination delivers antigen directly to an area with higher number of antigen-presenting cells. Therefore, it could produce equivalent or higher antibody titres than conventional intramuscular vaccination even when a lower dose is given. This study aimed to compare the antibody response in cattle vaccinated intramuscularly with 1mL of inactivated rabies vaccine (Raksharab, Indian Immunologicals) against intradermally vaccinated cattle with 0.2mL of the same vaccine. The study was conducted in Haa province of Bhutan where rabies is not endemic. One hundred cattle from 27 farms were selected for the study. Virus neutralising antibody (VNA) response was measured using the fluorescent antibody virus neutralisation test on the day of vaccination (day 0) and 14, 30, 60 and 90 days later. Overall, 71% of intradermally vaccinated cattle and 89% of the intramuscularly vaccinated cattle produced an adequate response (≥0.5IU/mL). On days 14 and 30 post vaccination fewer cattle (P<0.02) in the intradermal group had adequate titres with 36% and 58%, respectively, having titres ≥0.5 IU/mL compared to the equivalent figures of 78% and 77% in the intramuscular group. The mean VNA titres were lower for the intradermal group than intramuscular group (p<0.001) with the mean difference being > 0.6 IU/mL. Although low dose intradermal vaccination did produce a detectable antibody response, it was inferior to intramuscular vaccination. Thus, although intradermal vaccination has the potential to reduce the cost of vaccination by reducing the dose required, this study showed that a single dose of 0.2 mL intradermally was inferior to an intramuscular dose of 1 mL. Further research evaluating dose and dose regimen is needed before intradermal vaccination using the Raksharab rabies vaccine can be recommended in cattle.

show abstract

“…Further studies are needed, in particular on the use of a booster vaccination 60 days after primary vaccination, or on the use of a higher dose than the 0.2 IU/mL used in this study. The latter is likely to have lower costs and be more feasible, and increasing the intradermal dose is easier in cattle than humans as cattle skin is relatively thick and it is therefore easier to administer larger quantities of vaccine at one site (39).…”

Section: Discussionmentioning

confidence: 99%

Comparison of antibody titres between intradermal and intramuscular rabies vaccination using inactivated vaccine in cattle in Bhutan.

Wangmo

¹

,

Laven

²

,

Cliquet

³

et al. 2018

Preprint

0

View full text Add to dashboard Cite

In developing countries, the cost of vaccination limits the use of prophylactic rabies vaccination, especially in cattle. Intradermal vaccination delivers antigen directly to an area with higher number of antigen-presenting cells. Therefore, it could produce equivalent or higher antibody titres than conventional intramuscular vaccination even when a lower dose is given. Abstract 11In developing countries, the cost of vaccination limits the use of prophylactic rabies 12 vaccination, especially in cattle. Intradermal vaccination delivers antigen directly to an area 13 with higher number of antigen-presenting cells. Therefore, it could produce equivalent or 14 higher antibody titres than conventional intramuscular vaccination even when a lower dose is 15 given. 16This study aimed to compare the antibody response in cattle vaccinated intramuscularly with 17 1mL of inactivated rabies vaccine (Raksharab, Indian Immunologicals) against intradermally 18 vaccinated cattle with 0.2mL of the same vaccine. The study was conducted in Haa province 19 of Bhutan where rabies is not endemic. One hundred cattle from 27 farms were selected for 20 the study. Virus neutralising antibody (VNA) response was measured using the fluorescent 21 antibody virus neutralisation test on the day of vaccination (day 0) and 14, 30, 60 and 90 days 22 later. 23Overall, 71% of intradermally vaccinated cattle and 89% of the intramuscularly vaccinated 24 cattle produced a protective response (≥0.5IU/mL). This difference was significant (P<0.02) 25 on days 14 and 30 post vaccination with 36 and 58% in the intradermal group having titres 2 26 ≥0.5 IU/mL respectively compared to the equivalent figures of 78 and 77% in the 27 intramuscular group. The mean VNA titres were lower for intradermal group than 28 intramuscular group (p<0.001) with the mean difference being greater than 0.6 IU/mL. 29Although low dose intradermal vaccination did produce a detectable antibody response, it 30 was inferior to intramuscular vaccination. Thus, although intradermal vaccination has the 31 potential to reduce the cost of vaccination by reducing the dose required, this study showed 32 that a single dose of 0.2mL intradermally was inferior to an intramuscular dose of 1mL. 33Further research evaluating dose and dose regimen is needed before intradermal vaccination 34 using the Raksharab rabies vaccine can be recommended in cattle. 48 for every 2.5 cattle) of which 40% are stray dogs, and 31% owned but free roaming (12). 49Mass vaccination against rabies and sterilization of dogs have been carried out throughout the 50 country on an annual basis to reduce the risk of rabies. However, preventive control measures 51 in cattle, especially vaccination, have been a lower priority, because the risks of virus 52 transmission through cattle are low (13). Nevertheless, in endemic areas of Bhutan, rabies 53 remains common in cattle and causes considerable economic losses to smallholder cattle 54 farmers. Until rabies is eliminated in the reservoir hosts (principally dogs), free movement...

show abstract

Enhancement of the immune response by intradermal vaccination in cattle with enterotoxigenic Escherichia coli (ETEC) vaccine without adjuvant

Cited by 9 publications

References 10 publications

Insights into the mechanism of a novel shockwave-assisted needle-free drug delivery device driven by in situ-generated oxyhydrogen mixture which provides efficient protection against mycobacterial infections

Insights into the mechanism of a novel shockwave-assisted needle-free drug delivery device driven by in situ-generated oxyhydrogen mixture which provides efficient protection against mycobacterial infections

Comparison of antibody titres between intradermal and intramuscular rabies vaccination using inactivated vaccine in cattle in Bhutan

Comparison of antibody titres between intradermal and intramuscular rabies vaccination using inactivated vaccine in cattle in Bhutan.

Contact Info

Product

Resources

About